



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

Annexure - III

DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
MULTIPLE CHOICE QUESTIONS

Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry



CANDIDATE AND ASSESSOR INFORMATION

Course code: CT04

Candidate Name

PRITHIVIRAT S.

Assessor Name

Dr. VISHAY KUMAR

Date of Assessment

16.9.2017

Assessor Position

ASSISTANT PROFESSOR

Questions and Answers:

1. Which of the following regarding pulmonary hypertension (PH) is FALSE?

A. PH has many underlying etiologies

B. The disease affects the left side of the heart

C. The hemodynamic definition of PH is a mean pulmonary arterial pressure (PAP) greater than or equal to 25 mmHg

D. Pulmonary arterial hypertension (PAH) is a subset of PH

2. Which of the following regarding pulmonary arterial hypertension (PAH) is FALSE?



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- A. The disease affects men much more than women
- B. Non-specific symptoms such as fatigue and edema present clinically
- C. Catheterization is required when PH is suspected
- D. Underlying causes and PCWP or LVEDP are evaluated

3. Which of the following regarding PAH is FALSE?

- A. Vasoconstriction is an issue
- B. Vascular wall remodeling is an issue
- C. There is a cure for PAH
- D. The balance of vasoconstriction and vasodilation may indicate PAH

4. All of the following are true regarding calcium channel blockers (CCBs) in PAH EXCEPT

- A. CCBs have a selective effect on vascular smooth muscle
- B. Normal physiologic doses are sufficient for treatment purposes
- C. Adverse effects must be considered
- D. Long-term clinical response is less than 10%

5. Which of the following regarding epoprostenol is FALSE?

- A. The drug is a prostacyclin analog



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- B. There are two products: Flolan and Veletri
- C. The drug improves mortality
- D. The drug is selective

6. Which of the following regarding treprostinil is FALSE?

- A. It has a longer half-life than epoprostenol
- B. It is also shown to have a survival benefit
- C. It has a higher cost than epoprostenol
- D. It is stable at room temperature without a need for a back-up cassette.

7. Treprostinil, similar to epoprostenol, has two products.

- A. True
- B. False

8. Regarding iloprost, which of the following is FALSE?

- A. It is a prostacyclin analog
- B. It is approved for PAH WHO class 3 or 4 symptoms
- C. Very few doses are given per day
- D. There is a significant improvement in 6MWD and hemodynamics

9. Which of the following regarding bosentan is TRUE?



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- A. It is an ET-1 receptor agonist
- B. It is safe to use in pregnant women
- C. It is highly selective for the endothelin A (ETA) receptor
- D. It has many drug interactions

10. Which of the following regarding ambrisentan is FALSE?

- A. It is a non-selective ETA antagonist
- B. Teratogenicity is an issue
- C. Drug interactions are still concerning

11. All of the following are true regarding macitentan EXCEPT

- A. It is safe to use in pregnant women
- B. It is a tissue selective ET-1 receptor antagonist
- C. Hepatotoxicity is a concern
- D. Drug interactions are a concern



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

Annexure - III

DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
MULTIPLE CHOICE QUESTIONS

Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry



CANDIDATE AND ASSESSOR INFORMATION

Course code: CT04

Candidate Name **RAVEEN . S,**

Assessor Name **Dr. VIJAY KUMAR**

Date of Assessment **16 . 9 . 2017**

Assessor Position **ASSISTANT PROFESSOR**

Questions and Answers:

1. Which of the following regarding pulmonary hypertension (PH) is FALSE?

A. PH has many underlying etiologies

B. The disease affects the left side of the heart

C. The hemodynamic definition of PH is a mean pulmonary arterial pressure (PAP) greater than or equal to 25 mmHg

D. Pulmonary arterial hypertension (PAH) is a subset of PH

2. Which of the following regarding pulmonary arterial hypertension (PAH) is FALSE?



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- A. The disease affects men much more than women
- B. Non-specific symptoms such as fatigue and edema present clinically
- C. Catheterization is required when PH is suspected
- D. Underlying causes and PCWP or LVEDP are evaluated

3. Which of the following regarding PAH is FALSE?

- A. Vasoconstriction is an issue
- B. Vascular wall remodeling is an issue
- C. There is a cure for PAH
- D. The balance of vasoconstriction and vasodilation may indicate PAH

4. All of the following are true regarding calcium channel blockers (CCBs) in PAH EXCEPT

- A. CCBs have a selective effect on vascular smooth muscle
- B. Normal physiologic doses are sufficient for treatment purposes
- C. Adverse effects must be considered
- D. Long-term clinical response is less than 10%

5. Which of the following regarding epoprostenol is FALSE?

- A. The drug is a prostacyclin analog



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- B. There are two products: Flolan and Veletri
- C. The drug improves mortality
- D. The drug is selective

6. Which of the following regarding treprostinil is FALSE?

- A. It has a longer half-life than epoprostenol
- B. It is also shown to have a survival benefit
- C. It has a higher cost than epoprostenol
- D. It is stable at room temperature without a need for a back-up cassette.

7. Treprostinil, similar to epoprostenol, has two products.

- A. True
- B. False

8. Regarding iloprost, which of the following is FALSE?

- A. It is a prostacyclin analog
- B. It is approved for PAH WHO class 3 or 4 symptoms
- C. Very few doses are given per day
- D. There is a significant improvement in 6MWD and hemodynamics

9. Which of the following regarding bosentan is TRUE?



SRI LAKSHMI NARAYANA INSTITUTE OF HIGHER EDUCATION
AND RESEARCH

- A. It is an ET-1 receptor agonist
- B. It is safe to use in pregnant women
- C. It is highly selective for the endothelin A (ETA) receptor
- D. It has many drug interactions

10. Which of the following regarding ambrisentan is FALSE?

- A. It is a non-selective ETA antagonist
- B. Teratogenicity is an issue
- C. Drug interactions are still concerning

11. All of the following are true regarding macitentan EXCEPT

- A. It is safe to use in pregnant women
- B. It is a tissue selective ET-1 receptor antagonist
- C. Hepatotoxicity is a concern
- D. Drug interactions are a concern



Sri Lakshmi Narayana Institute of Medical Sciences



This is to certify that _____Praveen.S(U13MB231)_ has actively participated in the Value Added Course on **DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION** held during August - September 2017 Organized by Sri Lakshmi Narayana Institute of Medical Sciences, Pondicherry- 605 502, India.


Dr. Prakash Rao Balan
RESOURCE PERSON


Dr. Vijay Kumar
COORDINATOR



Sri Lakshmi Narayana Institute of Medical Sciences



This is to certify that _____ Praveena.M.FM(U13MB232)_ has actively participated in the Value Added Course on DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION held during August - September 2017 Organized by Sri Lakshmi Narayana Institute of Medical Sciences, Pondicherry- 605 502, India.

Dr. Prakash Rao Balan
RESOURCE PERSON

Dr. Vijay Kumar
COORDINATOR

Student Feedback Form

Course Name: DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION

Subject Code: CT 04

Name of Student: PRITHIVIRAJ S Roll No.: U13MB233

We are constantly looking to improve our classes and deliver the best training to you. Your evaluations, comments and suggestions will help us to improve our performance

Sl. NO	Particulars	1	2	3	4	5
1	Objective of the course is clear					✓
2	Course contents met with your expectations				✓	
3	Lecturer sequence was well planned			✓		
4	Lectures were clear and easy to understand					✓
5	Teaching aids were effective					✓
6	Instructors encourage interaction and were helpful					✓
7	The level of the course					✓
8	Overall rating of the course	1	2	3	4	5 ✓

* Rating: 5 - Outstanding; 4 - Excellent; 3 - Good; 2 - Satisfactory; 1 - Not-Satisfactory

Suggestions if any:

SATISFACTORY.

Prithiviraj S
Signature

Date: 16. 9. 2017

Student Feedback Form

Course Name: DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION

Subject Code: CT 04

Name of Student: PRAVEEN S Roll No.: U13MB231

We are constantly looking to improve our classes and deliver the best training to you. Your evaluations, comments and suggestions will help us to improve our performance

Sl. NO	Particulars	1	2	3	4	5
1	Objective of the course is clear					✓
2	Course contents met with your expectations				✓	
3	Lecturer sequence was well planned					✓
4	Lectures were clear and easy to understand					✓
5	Teaching aids were effective					✓
6	Instructors encourage interaction and were helpful				✓	
7	The level of the course					✓
8	Overall rating of the course	1	2	3	4	✓5

* Rating: 5 - Outstanding; 4 - Excellent; 3 - Good; 2 - Satisfactory; 1 - Not-Satisfactory

Suggestions if any:

EXCELLENT .

Praveen S
Signature

Date: 16.9.2017

